1996
DOI: 10.1016/s0002-9378(96)80013-5
|View full text |Cite
|
Sign up to set email alerts
|

Does the use of a tocolytic agent affect the success rate of external cephalic version?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
23
0
10

Year Published

1999
1999
2015
2015

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(35 citation statements)
references
References 7 publications
1
23
0
10
Order By: Relevance
“…However, the rate of prolonged decelerations is not reported in all studies [8,9]. Furthermore, the rates differ widely between studies, reflecting the different definitions used [4].…”
Section: Discussionmentioning
confidence: 99%
“…However, the rate of prolonged decelerations is not reported in all studies [8,9]. Furthermore, the rates differ widely between studies, reflecting the different definitions used [4].…”
Section: Discussionmentioning
confidence: 99%
“…This is in spite of our points about why ECV could be more difficult in our group of women. The other alternative of using tocolysis only in nulliparous women, as has been advocated by some, 9 could have led to fewer overall successes. This is because the effect of tocolysis seemed most marked in the small group of multiparous women.…”
Section: Discussionmentioning
confidence: 99%
“…7 Tocolysis for all women increases success rates from approximately 40% to 55%. 8,9 Therefore, of the 60 women out of 100 who have had a failed attempt without tocolysis, a further 15 (25%) could reasonably be expected to have a second successful attempt with tocolysis. To detect an increase in the incidence of cephalic presentation from 5% to 25% with 90% power (a ¼ 0.05), 124 patients were required.…”
Section: Methodsmentioning
confidence: 99%
“…Marquette et al ont é galement prouvé l'utilité de la ritodrine en i.v. par rapport au placebo chez les patientes nullipares supé rieures ou é gales à 36 SA [5]. Cette même é quipe a de plus comparé l'utilisation de la nitroglycé rine en SL (deux bouffé es de 400 mg) à celle d'un placebo chez des patientes multipares [6].…”
Section: Discussionunclassified